<p>Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk. Listen as Kevin Hennegan, Lisa Erickson and Sarah Roemer take us through several considerations when Playing the Comparability Game in Biotherapeutics Development.  </p>

Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk. Listen as Kevin Hennegan, Lisa Erickson and Sarah Roemer take us through several considerations when Playing the Comparability Game in Biotherapeutics Development.

<p>Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk. Listen as Kevin Hennegan, Lisa Erickson and Sarah Roemer take us through several considerations when Playing the Comparability Game in Biotherapeutics Development. &nbsp;</p>

Apples to Apples: Playing the Comparability Game in Biotherapeutics Development

Cell and gene therapies have made impressive clinical progress but continue to face big hurdles. Nothing is standard about study design, study conduct or regulatory process in this specialized area.

Share Apples to Apples: Playing the Comparability Game in Biotherapeutics Development

Sign up to save your podcasts

Apples to Apples: Playing the Comparability Game in Biotherapeutics Development

Apples to Apples: Playing the Comparability Game in Biotherapeutics Development